Replimune Q1 net loss $42.3M; CERPASS trial hits 180-patient enrollment target

Replimune Group, Inc.

2023-Q1 EPS reported -$0.78

Cash & short-term investments $395.1M as of June 30, 2022, vs $395.7M at March 31, 2022.
Net loss $42.3M for Q1 ended June 30, 2022, up from $27.3M year-over-year; R&D expenses rose to $29.5M.
CERPASS registration trial for RP1 in CSCC reached target enrollment of 180 patients; primary data expected H1 2023.
First 75 patients enrolled in IGNYTE anti-PD1 failed melanoma cohort; data snapshot with 6-month follow-up expected Q4 2022.
Phase 2 development program for RP2/3 in SCCHN, HCC, and CRC expected to initiate Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.